Larimar Therapeutics (LRMR) Stock Analysis: AI Score & Alternative Data
Alt-data signals are cooling for Larimar Therapeutics
Is Larimar Therapeutics a buy right now? The alternative data says hold. This LRMR stock analysis is built on the 25+ alternative data signals AltIndex tracks on Larimar Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 49/100: a Hold. The stock trades at $2.16 with a $263M market cap.
The soft spots over the past 90 days: web traffic down 17.7% to 5K monthly visits. The rest of the signal set is holding steady, which keeps LRMR at a hold rather than a sell.
LRMR’s broader alt-data profile also covers job postings (3 open roles), headcount (83 employees, according to LinkedIn), and sentiment (100/100). Every signal links to its own page with full history, the LRMR technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on LRMR is just below.
Larimar Therapeutics AI Stock Analysis
Larimar Therapeutics is a biotechnology company focused on developing treatments for rare and complex diseases. The company's primary objective is to deliver transformative therapies through scientific innovation and technological advancements.
Analysis generated October 2, 2026.
Recent Larimar Therapeutics Stock Alerts
|
Larimar Therapeutics | October 13 Price is down by -6.7% in the last 24h. |
|
Larimar Therapeutics | October 5 Price is down by -6.1% in the last 24h. |
|
Larimar Therapeutics | September 25 Price is down by -6% in the last 24h. |
|
Larimar Therapeutics | September 24 Price is down by -7% in the last 24h. |
Larimar Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 5K | 17.7% | |
| Job Posts | 3 | 0% | |
| LinkedIn Employees | 83 | 1.2% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 75 | 837.5% | |
| Stocktwits Mentions | 9 | 81.3% | |
| News Mentions | 0 | 100.0% | |
| Stocktwits Subscribers | 5K | 0% | |
| 4chan Mentions | 0 | N/A |
About Larimar Therapeutics (LRMR)
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform.
| Price | $2.16 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $263M |
| Year Range | $2 – $6 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Larimar Therapeutics News
View more →
Larimar Therapeutics Reports Second Quarter 2026 Financial and Business UpdateAugust 4 - GlobeNewswire |
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 21 - GlobeNewswire |
|
Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp TherapyJuly 15 - Yahoo Entertainment |
|
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRJuly 14 - GlobeNewswire |
|
See Larimar Therapeutics’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for LRMR, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREELarimar Therapeutics Earnings & Financial Performance
View all earnings →Larimar Therapeutics Insider Trading Activity
View all →| Hamilton Thomas Edward filed to sell 714,798 shares at $0.0. Jul 6 '26 |
| SHERMAN JEFFREY W filed to sell 5,000 shares at $0.0. Feb 27 '26 |
| THOMAS FRANK E filed to sell 7,000 shares at $0.0. Feb 27 '26 |
| Hamilton Thomas Edward filed to sell 664,798 shares at $0.0. Feb 27 '26 |
| DEERFIELD MANAGEMENT COMPANY, L.P. filed to sell 8,153,107 shares at $0.0. Feb 27 '26 |
Larimar Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Larimar Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Greenwich LifesciencesGLSI |
$15.50 12.8% | $261M | 55 |
 |
Century TherapeuticsIPSC |
$1.38 4.2% | $261M | 49 |
 |
Q32 BioQTTB |
$8.06 7.8% | $260M | 55 |
 |
2Seventy BioTSVT |
$4.99 0.0% | $266M | 44 |
 |
Inhibikase TherapeuticsIKT |
$1.76 4.6% | $257M | 47 |
Explore Larimar Therapeutics Data
Frequently Asked Questions: Larimar Therapeutics (LRMR)
Larimar Therapeutics has an AltIndex AI Score of 49/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
49/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Larimar Therapeutics (LRMR) stock is $2.16 with a market cap of $263M.
As of today, Larimar Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Larimar Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Larimar Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The LRMR stock price chart above shows Larimar Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Larimar Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Larimar Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
